111 related articles for article (PubMed ID: 16647240)
41. The social phobia psychotherapy research network. The first multicenter randomized controlled trial of psychotherapy for social phobia: rationale, methods and patient characteristics.
Leichsenring F; Hoyer J; Beutel M; Herpertz S; Hiller W; Irle E; Joraschky P; Konig HH; de Liz TM; Nolting B; Pohlmann K; Salzer S; Schauenburg H; Stangier U; Strauss B; Subic-Wrana C; Vormfelde S; Weniger G; Willutzki U; Wiltink J; Leibing E
Psychother Psychosom; 2009; 78(1):35-41. PubMed ID: 18852500
[TBL] [Abstract][Full Text] [Related]
42. The effect of attributional processes concerning medication taking on return of fear.
Powers MB; Smits JA; Whitley D; Bystritsky A; Telch MJ
J Consult Clin Psychol; 2008 Jun; 76(3):478-90. PubMed ID: 18540741
[TBL] [Abstract][Full Text] [Related]
43. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
[TBL] [Abstract][Full Text] [Related]
44. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up.
Prasko J; Dockery C; Horácek J; Houbová P; Kosová J; Klaschka J; Pasková B; Praskova H; Seifertová D; Záleský R; Höschl C
Neuro Endocrinol Lett; 2006 Aug; 27(4):473-81. PubMed ID: 16891998
[TBL] [Abstract][Full Text] [Related]
45. Imagery rescripting versus in vivo exposure in the treatment of snake fear.
Hunt M; Fenton M
J Behav Ther Exp Psychiatry; 2007 Dec; 38(4):329-44. PubMed ID: 17949681
[TBL] [Abstract][Full Text] [Related]
46. Enhancing acupuncture by low dose naltrexone.
Hesselink JM; Kopsky DJ
Acupunct Med; 2011 Jun; 29(2):127-30. PubMed ID: 21415049
[TBL] [Abstract][Full Text] [Related]
47. Augmenting in vivo exposure with fear antagonistic actions: a preliminary test.
Wolitzky KB; Telch MJ
Behav Ther; 2009 Mar; 40(1):57-71. PubMed ID: 19187817
[TBL] [Abstract][Full Text] [Related]
48. Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying.
Rothbaum BO; Anderson P; Zimand E; Hodges L; Lang D; Wilson J
Behav Ther; 2006 Mar; 37(1):80-90. PubMed ID: 16942963
[TBL] [Abstract][Full Text] [Related]
49. Naltrexone fails to increase pain affect in response to inflammatory pain in a novel escape/avoidance paradigm.
Uhelski ML; Fuchs PN
Physiol Behav; 2009 Sep; 98(3):263-7. PubMed ID: 19505486
[TBL] [Abstract][Full Text] [Related]
50. Assessment of opiate modulation of pain and nociceptive responding in young adults with a parental history of hypertension.
France CR; al'absi M; Ring C; France JL; Brose J; Spaeth D; Harju A; Nordehn G; Wittmers LE
Biol Psychol; 2005 Dec; 70(3):168-74. PubMed ID: 15936866
[TBL] [Abstract][Full Text] [Related]
51. Common factors of cognitive therapy and interpersonal psychotherapy in the treatment of social phobia.
Stangier U; Von Consbruch K; Schramm E; Heidenreich T
Anxiety Stress Coping; 2010 May; 23(3):289-301. PubMed ID: 19662551
[TBL] [Abstract][Full Text] [Related]
52. [Swallowing phobia: a case report].
de Lucas-Taracena MT; Ibarra I
Actas Esp Psiquiatr; 2001; 29(6):411-3. PubMed ID: 11730580
[TBL] [Abstract][Full Text] [Related]
53. [Naltrexone--an effective aid in the psychosocial rehabilitation process of former opiate dependent patients].
Ladewig D
Ther Umsch; 1990 Mar; 47(3):247-50. PubMed ID: 2187266
[TBL] [Abstract][Full Text] [Related]
54. Adrenocortical and nociceptive responses to opioid blockade in hypertension-prone men and women.
al'Absi M; France C; Harju A; France J; Wittmers L
Psychosom Med; 2006; 68(2):292-8. PubMed ID: 16554396
[TBL] [Abstract][Full Text] [Related]
55. Opioid antagonist affects behavioral effects of exposure in vivo.
Arntz A; Merckelbach H; de Jong P
J Consult Clin Psychol; 1993 Oct; 61(5):865-70. PubMed ID: 7902369
[TBL] [Abstract][Full Text] [Related]
56. Fear activation and distraction during the emotional processing of claustrophobic fear.
Telch MJ; Valentiner DP; Ilai D; Young PR; Powers MB; Smits JA
J Behav Ther Exp Psychiatry; 2004 Sep; 35(3):219-32. PubMed ID: 15262218
[TBL] [Abstract][Full Text] [Related]
57. Naltrexone implants as treatment for heroin dependence: part I.
Byrne A; Graham G; Hallinan R; Murnion B
Addict Biol; 2005 Jun; 10(2):201; author reply 201-2. PubMed ID: 16191674
[No Abstract] [Full Text] [Related]
58. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial.
Powers MB; Smits JA; Telch MJ
J Consult Clin Psychol; 2004 Jun; 72(3):448-54. PubMed ID: 15279528
[TBL] [Abstract][Full Text] [Related]
59. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?
Ramanathan S; Panksepp J; Johnson B
Psychosomatics; 2012; 53(6):591-4. PubMed ID: 22480625
[No Abstract] [Full Text] [Related]
60. The effect of the decreased safety behaviors on anxiety and negative thoughts in social phobics.
Kim EJ
J Anxiety Disord; 2005; 19(1):69-86. PubMed ID: 15488368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
